Preclinical models of psoriasis

Veterinary Pathology

Volumn 45, Issue 4, 2008, Pages 563-575

  Danilenko, D M ^a,b  

^a GENENTECH INC   (United States)

^b MS 72B ^*  (United States)

Author keywords

Animal disease models; Human epidermis; In vitro models; Mouse; Psoriasis

Indexed keywords

ANIMALIA; MURINAE;

ANIMAL; DISEASE MODEL; IMMUNOLOGY; KERATINOCYTE; MOUSE; PATHOLOGY; PSORIASIS; RAT; REVIEW; T LYMPHOCYTE; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; DISEASE MODELS, ANIMAL; KERATINOCYTES; MICE; PSORIASIS; RATS; T-LYMPHOCYTES;

EID: 54749085848     PISSN: 03009858     EISSN: 15442217     Source Type: Journal    
DOI: 10.1354/vp.45-4-563     Document Type: Article

References (57)

1. Barker CL, McHale MT, Gillies AK, Waller J, Pearce DM, Osborne J, Hutchinson PE, Smith GM, Pringle JH: The development and characterization of an in vitro model of psoriasis. J Invest Dermatol 123:892-901, 2004
2. Barker JN: The pathophysiology of psoriasis. Lancet 338:227-230, 1991
3. Barlow SC, Collins RG, Ball NJ, Weaver CT, Schoeb TR, Bullard DC: Psoriasiform dermatitis susceptibility in Itgb2(tm1Bay) PL/J mice requires low-level CD18 expression and at least two additional loci for progression to severe disease. Am J Pathol 163:197-202, 2003
4. Bhagavathula N, Nerusu KC, Fisher GJ, Liu G, Thakur AB, Gemmell L, Kumar S, Xu ZH, Hinton P, Tsurushita N, Landolfi NF, Voorhees JJ, Varani J: Amphiregulin and epidermal hyperplasia: amphi- regulin is required to maintain the psoriatic pheno- type of human skin grafts on severe combined immunodeficient mice. Am J Pathol 166:1009-1016, 2005
5. Blauvelt A: New concepts in the pathogenesis and treatments of psoriasis: key roles for IL-23, IL-17A and TGF-β1. Expert Rev Dermatol 2:69-78, 2007
6. Blumberg H, Conklin D, Xu WF, Grossmann A, Brender T, Carollo S, Eagan M, Foster D, Halde- man BA, Hammond A, Haugen H, Jelinek L, Kelly JD, Madden K, Maurer MF, Parrish-Novak J, Prunkard D, Sexson S, Sprecher C, Waggie K, West J, Whitmore TE, Yao L, Kuechle MK, Dale BA, Chandrasekher YA: Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell 104:9-19, 2001
7. Boniface K, Bernard FX, Garcia M, Gurney AL, Lecron JC, Morel F: IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 174:3695-3702, 2005
8. Boniface K, Diveu C, Morel F, Pedretti N, Froger J, Ravon E, Garcia M, Venereau E, Preisser L, Guignouard E, Guillet G, Dagregorio G, Pène J, Moles JP, Yssel H, Chevalier S, Bernard FX, Gascan H, Lecron JC: Oncostatin M secreted by skin infiltrating T lymphocytes is a potent keratinocyte activator involved in skin inflammation. J Immunol 178:4615-4622, 2007
9. Boyman O, Hefti HP, Conrad C, Nickoloff BJ, Suter M, Nestle FO: Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med 199:731-736, 2004
10. Bullard DC, Scharffetter-Kochanek K, McArthur MJ, Chosay JG, McBride ME, Montgomery CA, Beaudet AL: A polygenic mouse model of psoriasi- form skin disease in CD18-deficient mice. Proc Natl Acad Sci USA 93:2116-2121, 1996
11. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357:1842-1847, 2001
12. Detmar M, Brown LF, Schon MP, Elicker BM, Velasco P, Richard L, Fukumura D, Monsky W, Claffey KP, Jain RK: Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol 111:1-6, 1998
13. Gazel A, Rosdy M, Bertino B, Tornier C, Sahuc F, Blumenberg M: A characteristic subset of psoriasis- associated genes is induced by oncostatin-M in reconstituted epidermis. J Invest Dermatol 126:2647-2657, 2006
14. Gottlieb AB, Miller B, Lowe N, Shapiro W, Hudson C, Bright R, Ling M, Magee A, McCall CO, Rist T, Dummer W, Walicke P, Bauer RJ, White M, Garovoy M: Subcutaneously administered efalizu- mab (anti-CD11a) improves and signs and symptoms of moderate to severe plaque psoriasis. J Cut Med Surg 7:198-207, 2003
15. Guo L, Yu Q-C, Fuchs E: Targeting expression of keratinocyte growth factor to keratinocytes elicits striking changes in epithelial differentiation in transgenic mice. EMBO J 12:973-986, 1993
16. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nature Immunol 6:1123-1132, 2005
17. HogenEsch H, Gijbels MJ, Offerman E, van Hooft J, van Bekkum DW, Zurcher C: A spontaneous mutation characterized by chronic proliferative dermatitis in C57BL mice. Am J Pathol 143:972-982, 1993
18. HogenEsch H, Torregrosa SE, Boggess D, Sundberg BA, Carroll J, Sundberg JP: Increased expression of type 2 cytokines in chronic proliferative dermatitis (cpdm) mutant mice and resolution of inflammation following treatment with IL-12. Eur J Immunol 31:734-742, 2001
19. Hong K, Chu A, Ludviksson BR, Berg EL, Ehrhardt RO: IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasislike skin disorder. J Immunol 162:7480-7491, 1999
20. Hong K, Berg EL, Ehrhardt RO: Persistence of pathogenic CD4+ Th1-like cells in vivo in the absence of IL-12 but in the presence of autoantigen. J Immunol 166:4765-4772, 2001
21. Inman RD, Scofield RH: Etiopathogenesis of ankylosing spondylitis and reactive arthritis. Curr Opin Rheumatol 6:360-370, 1994
22. Kauffman CL, Aria N, Toichi E, McCormick TS, Cooper KD, Gottlieb AB, Everitt DE, Frederick B, Zhu Y, Graham MA, Pendley CE, Mascelli MA: A phase I study evaluating the safety, pharmacokinet- ics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 123:1037-1044, 2004
23. Kess D, Peters T, Zamek J, Wickenhauser C, Tawadros S, Loser K, Varga G, Grabbe S, Nischt R, Sunderkotter C, Müller W, Krieg T, Scharffetter- Kochanek K: CD4+ T cell-associated pathophysiol- ogy critically depends on CD18 gene dose effects in a murine model of psoriasis. J Immunol 171:5697- 5706, 2003
24. Kopp T, Kieffer JD, Rot A, Strommer S, Stingl G, Kupper TS: Inflammatory skin disease in K14/p40 transgenic mice: evidence for interleukin-12-like activities of p40. J Invest Dermatol 117:618-626, 2001
25. Kopp T, Lenz P, Bello-Fernandez C, Kastelein RA, Kupper TS, Stingl G: IL-23 production by cosecre- tion of endogenous p19 and transgenic p40 in keratin 14/p40 transgenic mice: evidence for enhanced cutaneous immunity. J Immunol 170:5438-5444, 2003
26. Krueger JG, Bowcock A: Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 64 (Suppl 2): ii30-ii36, 2005
27. Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F, Dhodapkar M, Krueger JG: Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 199:125-130, 2004
28. Li AG, Wang D, Feng XH, Wang XJ: Latent TGFp1 overexpression in keratinocytes results in a severe psoriasis-like skin disorder. EMBO J 23:1770-1781, 2004
29. Lowes MA, Bowcock AM, Krueger JG: Pathogen- esis and therapy of psoriasis. Nature 445:866-873, 2007
30. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356:385-390, 2000
31. Nestle FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, Boyman O, Burg G, Liu Y-J, Gilliet M: Plasmacytoid predendritic cells initiate psoriasis through interferon-a production. J Exp Med 202:135-143, 2005
32. Nickoloff BJ: Keratinocytes regain momentum as instigators of cutaneous inflammation. Trends Mol Med 12:102-106, 2006
33. Nickoloff BJ: Cracking the cytokine code in psoriasis. Nature Med 13:242-244, 2007
34. Nickoloff BJ, Nestle FO: Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 113:1664-1675,2004
35. Nickoloff BJ, Wrone-Smith T: Injection of prepsoriatic skin with CD4+ T cells induces psoriasis. Am J Pathol 155:145-158, 1999
36. Park H, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C: A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nature Immunol 6:1133-1141, 2005
37. Pasparakis M, Courtois G, Hafner M, Schmidt- Supprian M, Nenci A, Toksoy A, Krampert M, Goebeler M, Gillitzer R, Israel A, Krieg T, Rajewsky K, Haase I: TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature 417:861-866, 2002
38. Pauls K, Schon M, Kubitza RC, Homey B, Wiesen- born A, Lehmann P, Ruzicka T, Parker CM, Schon MP: Role of integrin alphaE(CD103)beta7 for tissue-specific epidermal localization of CD8+ T lymphocytes. J Invest Dermatol 117:569-575, 2001
39. Pittelkow MR: Psoriasis: more than skin deep. Nat Med 11:17-18, 2005
40. Sa S, Valdez PA, Wu J, Jung K, Zhong F, Hall L, Kasman I, Winer J, Modrusan Z, Danilenko DM, Ouyang W: The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 178:2229-2240, 2007
41. SanoS,ChanKS,CarbajalS,CliffordJ,PeaveyM, Kiguchi K, Itami S, Nickoloff BJ, DiGiovanni J: Stat3 links activated keratinocytes and immuno- cytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 11:43-49, 2005
42. Schon MP: Animal models of psoriasis - what can we learn from them? J Invest Dermatol 112:405-410, 1999
43. Schon MP, Detmar M, Parker CM: Murine psoriasis-like disorder induced by naive CD4+ T cells. Nat Med 3:183-188, 1997
44. Schon MP, Schon M, Warren HB, Donohue JP, Parker CM: Cutaneous inflammatory disorder in integrin alphaE (CD103)-deficient mice. J Immunol 165:6583-6589, 2000
45. Seymour RE, Hasham MG, Cox GA, Shultz LD, HogenEsch H, Roopenian DC, Sundberg JP: Spontaneous mutations in the mouse Sharpin gene result in multiorgan inflammation, immune system dysreg ulation and dermatitis. Genes Immun 8:416-421, 2007
46. Stratis A, Pasparakis M, Rupec RA, Markur D, Hartmann K, Scharffetter-Kochanek K, Peters T, van Rooijen N, Krieg T, Haase I: Pathogenic role for skin macrophages in a mouse model of kerati- nocyte-induced psoriasis-like skin inflammation. J Clin Invest 116:2094-2104, 2006
47. Sundberg JP, France M, Boggess D, Sundberg BA, Jenson AB, Beamer WG, Shultz LD: Development and progression of psoriasiform dermatitis and systemic lesions in the flaky skin (fsn) mouse mutant. Pathobiology 65:271-286, 1997
48. Taurog JD, Maika SD, Simmons WA, Breban M, Hammer RE: Susceptibility to inflammatory disease in HLA-B27 transgenic rat lines correlates with the level of B27 expression. J Immunol 150:4168-4178, 1993
49. Toichi E, Torres G, McCormick TS, Chang T, Mascelli MA, Kauffman CL, Aria N, Gottlieb AB, Everitt DE, Frederick B, Pendley CE, Cooper KD: An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines and IL-12/IL-23 in psoriasis. J Immunol 177:4917-4926, 2006
50. Vassar R, Fuchs E: Transgenic mice provide new insights into the role of TGF-alpha during epidermal development and differentiation. Genes Dev 5:714-727, 1991
51. Voskas D, Jones N, Van Slyke P, Sturk C, Chang W, Haninec A, Babichev YO, Tran J, Master Z, Chen S, Ward N, Cruz M, Jones J, Kerbel RS, Jothy S, Dagnino L, Arbiser J, Klement G, Dumont DJ: A cyclosporine-sensitive psoriasis-like disease produced in Tie2 transgenic mice. Am J Pathol 166: 843-855, 2005
52. Wrone-Smith T, Nickoloff BJ: Dermal injection of immunocytes induces psoriasis. J Clin Invest 98:1878-1887, 1996
53. Yanagisawa H, Richardson JA, Taurog JD, Hammer RE: Characterization of psoriasiform and alopecic skin lesions in HLA-B27 transgenic rats. Am J Pathol 147:955-964, 1995
54. Xia YP, Li B, Hylton D, Detmar M, Yancopoulos GD, Rudge JS: Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 102:161-168, 2003
55. Zeigler M, Chi Y, Tumas DB, Bodary S, Tang H, Varani J: Anti-CD11a ameliorates disease in the human psoriatic skin-SCID mouse transplant model: comparison of antibody to CD11a with cyclosporin A and clobetasol propionate. Lab Invest 81:1253-1261, 2001
56. Zenz R, Eferl R, Kenner L, Florin L, Hummerich L, Mehic D, Scheuch H, Angel P, Tschachler E, Wagner EF: Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 437:369-375, 2005
57. Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, Ouyang W: Interleukin- 22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445:648-651, 2007